Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Fusion Antibodies Plc ( (GB:FAB) ) has issued an announcement.
Fusion Antibodies plc has secured a contract for a new stable Cell Line Development project with a US biotechnology company, expected to generate $250,000 in revenue by the end of 2025. This project underscores Fusion’s reputation for delivering high-quality therapeutic antibodies and is anticipated to provide a financial foundation for the fiscal year ending March 2026, with potential for future growth in cell line development projects.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a comprehensive range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top 10 global pharmaceutical companies, and aims to accelerate drug development through advanced technological platforms.
YTD Price Performance: 13.48%
Average Trading Volume: 1,706,954
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £7.68M
For an in-depth examination of FAB stock, go to TipRanks’ Stock Analysis page.